Revisiting Diagnosis: From Visualization to Molecular Detection
Cystoscopy has long been the cornerstone of NMIBC diagnosis, offering excellent sensitivity but imperfect detection of flat or occult lesions. The integration of enhanced imaging modalities, particularly blue-light cystoscopy (BLC), represents an important step forward, improving detection rates and reducing early recurrence. Urinary biomarkers are steadily transitioning from adjunctive tools to central players in diagnostic pathways. Contemporary urinary biomarker assays and emerging DNA-based platforms demonstrate promising sensitivity and negative predictive value, raising the possibility of reducing dependence on invasive diagnostic procedures. What is increasingly evident is that diagnosis in NMIBC is no longer a binary visual exercise but a multidimensional assessment integrating morphology, molecular biology, and risk prediction.
Risk Stratification
Risk stratification has traditionally relied on models such as EORTC and CUETO, tools that, while historically valuable, were derived from cohorts that do not reflect contemporary practice. Their limitations are particularly evident in the era of maintenance BCG, improved resection techniques, and evolving grading systems. The AUA/SUO framework has simplified bedside decision-making, yet its granularity, particularly within intermediate-risk disease, remains limited. Emerging artificial intelligence–driven models, such as PROGRxN-BCa, offer a glimpse into the future. By leveraging large datasets and modern classification systems, these tools provide superior discrimination and clinically meaningful sub-stratification. Risk assessment is increasingly shifting from static categorization to a dynamic, data-driven, and individualized approach. It is dynamic, data-driven, and increasingly individualized. The challenge moving forward will be integration, ensuring that these tools enhance, rather than complicate, clinical decision-making.
Therapeutic Evolution: Beyond BCG
Intravesical therapy remains the backbone of NMIBC management, and BCG continues to represent the gold standard for high-risk disease. Global shortages and treatment failures have forced the field to innovate. Sequential intravesical chemotherapy regimens, device-assisted delivery systems such as hyperthermic chemotherapy and TAR-200, and reverse thermal gels like UGN-102 are redefining how drugs interact with the urothelium. Simultaneously, immunotherapy has extended its reach into earlier disease states. Pembrolizumab has demonstrated clinically meaningful responses in BCG-unresponsive NMIBC, while novel agents such as N-803 and combination checkpoint strategies are reshaping expectations around bladder preservation. Gene therapy represents perhaps the most conceptually transformative advance. Agents like nadofaragene firadenovec exemplify a shift toward biologically engineered interventions with durable responses in otherwise refractory disease. Despite this progress, an important caveat remains: much of the evidence is derived from single-arm or early-phase trials. The field must now prioritize comparative effectiveness, sequencing strategies, and long-term outcomes.
Surveillance: From Rigid Protocols to Adaptive Monitoring
Few aspects of NMIBC impose as great a burden as surveillance. Frequent cystoscopy, while effective, comes at the cost of patient discomfort, procedural risk, and financial strain. Emerging biomarker-driven approaches, including circulating tumor DNA (ctDNA) and urinary tumor DNA (utDNA), introduce the possibility of adaptive surveillance. These platforms can detect minimal residual disease and early recurrence, often preceding visual detection. This paradigm shift has profound implications. Patients with persistently negative molecular profiles may safely undergo de-escalated surveillance, while those with early molecular recurrence could benefit from timely intervention. In essence, surveillance is evolving from a schedule-based model to a marker-based model, a transition that aligns closely with the principles of precision oncology.
A Unifying Perspective: Toward Patient-Centered Precision Care
Across diagnosis, risk stratification, treatment, and surveillance, a unifying theme emerges: the movement toward personalization. NMIBC management is no longer defined solely by tumor stage and grade. It is increasingly shaped by molecular signatures, treatment response, patient preferences, and health system realities. At the same time, innovation must be tempered by pragmatism. Cost-effectiveness, accessibility, and real-world implementation remain critical considerations, particularly for a disease that is among the most expensive malignancies to manage longitudinally.
Future Directions
The future of NMIBC care will likely be driven by three converging developments: incorporation of molecular profiling into routine practice, bladder-preserving strategies that limit morbidity without sacrificing oncologic control, and adaptive care pathways guided by real-time patient data. To achieve this, continued collaboration between clinicians, researchers, and industry will be essential, as will the generation of robust phase III and real-world evidence.
Conclusion
NMIBC is no longer a static disease managed by uniform algorithms. It is a dynamic, heterogeneous condition that demands nuanced, individualized care. As management continues to evolve beyond traditional paradigms, the overarching goal is to provide care that balances oncologic efficacy with patient-centered, data-driven, and sustainable approaches.
Written by: Sri Saran Manivasagam,1 Amar Kassim,2 Jay D. Raman,1
- Department of Urology, Penn State Health Milton S. Hershey Medical Center, Hershey, PA, USA.
- Pennsylvania State University College of Medicine, Hershey, PA, USA.